Theresa Juday, RPh, director, Specialty Product Development, CVS Health, discusses the potential of cognitive behavioral therapy to address health disparities in underserved communities.
Cognitive behavioral therapy (CBT), particularly digital CBT, has the potential to address health disparities prevalent in underserved communities nationwide, said Theresa Juday, RPh, director, Specialty Product Development, CVS Health.
Transcript
What impact may the evolution of CBT capabilities have on patient outcomes?
Not just around CBT, but in a more broader health care scope where I think for CBT or digital CBT in particular, it's important to think about how this helps to address a very important area of health care and one that we have seen conversations emerge easily in the last 5 years, and that is how we help address health disparities.
So from a digital perspective in particular, digital CBT can help to do that as well. So I talked a little bit more about addressing patients who have transportation issues or rural populations, populations where language is a barrier, that is something that all leads to health disparities. Also, people of color. The stigma around cognitive behavioral therapy as a whole in populations of color does exist, and digital CBT can help to address that concern as well.
Again, bringing it in house, they can do it in the comfort of their own home. They can make it a little bit more anonymous while still accessing the care that they need. Looking at how CBT and particularly digital CBT can not only improve health outcomes, but address some of those health disparity barriers that exist might be an important piece to the puzzle.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More